<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213937</url>
  </required_header>
  <id_info>
    <org_study_id>KAL-SCLC-01</org_study_id>
    <nct_id>NCT04213937</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer</brief_title>
  <official_title>The Efficacy and Safety of Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer: A Multicenter, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with
      topotecan as second-line treatment for patients with extensive stage small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 years post treatment</time_frame>
    <description>OS was defined as the time from the date of the first administration of trial regimen to the date of death from any cause (event) or last follow-up (censored data).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>1 years</time_frame>
    <description>Response evaluation disease progression defined by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) criteria.
Response (PR), refers to the number of cases with complete and partial response after treatment as a percentage of the total number of evaluable cases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>1 years</time_frame>
    <description>The time from treatment to tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE)</measure>
    <time_frame>3 years</time_frame>
    <description>Adverse events (AE) were monitored on an ongoing basis and classified according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. Patients were assessed for toxicities before each administration, and toxicity was graded accordingly</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">386</enrollment>
  <condition>Extensive Stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Drug: nab-paclitaxel 125mg/m2, i.v. d1, d8, Repeated every 3 weeks for 4-6 cycles.</description>
    <arm_group_label>nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Drug: Topotecan 1.25mg/m2/d, i.v, 1hour, d1-d5, Repeated every 3 weeks for 4-6 cycles.</description>
    <arm_group_label>Topotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.18 to 75years, male or female; 2.Histological or pathological diagnosis of small cell
        lung caner; 3.Progression or relapse after first-line chemotherapy, extensive disease;
        4.ECOG performance status of 0-2; 5.Life expectancy of 3 months or more; 6.Patient must be
        accessible for treatment and follow-up; 7.For women of child-bearing age, the pregnancy
        test results (serum or urine) within 72 hours before enrolment must be negative. They will
        take appropriate methods for contraception during the study; 8.Signed informed consent.

        Exclusion Criteria:

          1. symptomatic brain metastases;

          2. Uncontrolled serious medical conditions that, in the opinion of the investigator,
             would affect the ability of the subject to receive the study regimen, such as
             concomitant serious medical conditions, including severe heart disease,
             cerebrovascular disease, uncontrolled diabetes mellitus, uncontrolled hypertension,
             uncontrolled infection, active peptic ulcer, etc.;

          3. Have dementia, altered mental state or any mental illness that would prevent
             understanding or informed consent or fill out questionnaires;

          4. Received any investigational drug within 30 days of the planned first dose of this
             study treatment.

          5. Prior Grade ≥ 2 peripheral neuropathy(according to (NCI CTCAE), version 5.0);

          6. Known to be hypersensitive, highly sensitive, or intolerant to study-related
             medications or their excipients;

          7. Have malignant tumors in the past 5 years, except for clinically cured basal cell or
             squamous cell skin cancer, local prostate cancer after radical operation, and ductal
             carcinoma in situ after radical operation;

          8. Bone marrow function: Neutrophils &lt; 1.5×109/L, platelets &lt; 100×109/L, hemoglobin &lt; 90
             g/L; Hepatic and renal function: Serum creatinine &gt; 1.5×ULN; AST and ALT &gt; 2.5×ULN or
             &gt; 5×ULN in the presence of hepatic metastasis; Total bilirubin &gt;1.5×ULN;

          9. Patients need other anti-tumor drugs;

         10. Known HIV, hepatitis B/C virus positive ;

         11. The researchers considered the patients who were not suitable for enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jie MD Wang, PhD</last_name>
    <phone>86 13910704669</phone>
    <email>wangjiezgyxkxy@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>December 27, 2019</last_update_submitted>
  <last_update_submitted_qc>December 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jie Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>nab-paclitaxel Topotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

